HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin C Supplements Linked With Heart Benefits In Nurse’s Health Study

This article was originally published in The Tan Sheet

Executive Summary

Women who took 360 mg or more per day of vitamin C from diet and supplements reduced their risk of coronary heart disease (CHD) by 27% in a study published in the July 16 Journal of the American College of Cardiology

You may also be interested in...



AHA Advises Against Antioxidant Supplementation For CHD Prevention

Use of antioxidant supplementation for cardiovascular disease prevention is not supported by clinical trial data, according to a scientific advisory issued by the American Heart Association Aug. 3

Vitamin A, C, E Supplements For CVD, Cancer Without Sufficient Evidence

"The evidence is insufficient to recommend for or against the use of supplements" containing vitamins A, C, or E and certain vitamin combinations for the prevention of cancer or cardiovascular disease, the U.S. Preventive Services Task Force has determined

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129444

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel